Knight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
J Am Soc Echocardiogr. 2013 Dec;26(12):1474-81. doi: 10.1016/j.echo.2013.08.004. Epub 2013 Sep 12.
The etiology of flank pain sometimes experienced during the administration of ultrasound contrast agents is unknown. The aim of this study was to investigate whether microbubble ultrasound contrast agents are retained within the renal microcirculation, which could lead to either flow disturbance or local release of vasoactive and pain mediators downstream from complement activation.
Retention of lipid-shelled microbubbles in the renal microcirculation of mice was assessed by confocal fluorescent microscopy and contrast-enhanced ultrasound imaging with dose-escalating intravenous injection. Studies were performed with size-segregated microbubbles to investigate physical entrapment, after glycocalyx degradation and in wild-type and C3-deficient mice to investigate complement-mediated retention. Urinary bradykinin was measured before and after microbubble administrations. Renal contrast-enhanced ultrasound in human subjects (n = 13) was performed 7 to 10 min after the completion of lipid microbubble administration.
In both mice and humans, microbubble retention was detected in the renal cortex by persistent contrast-enhanced ultrasound signal enhancement. Microbubble retention in mice was linearly related to dose and occurred almost exclusively in cortical glomerular microvessels. Microbubble retention did not affect microsphere-derived renal blood flow. Microbubble retention was not influenced by glycocalyx degradation or by microbubble size, thereby excluding lodging, but was reduced by 90% (P < .01) in C3-deficient mice. Urinary bradykinin increased by 65% 5 min after microbubble injection.
Lipid-shelled microbubbles are retained in the renal cortex because of complement-mediated interactions with glomerular microvascular endothelium. Microbubble retention does not adversely affect renal perfusion but does generate complement-related intermediates that are known to mediate nociception and could be responsible for flank pain.
在使用超声造影剂时有时会出现侧腹痛,其病因尚不清楚。本研究旨在探讨脂质壳微泡超声造影剂是否会滞留在肾脏微循环中,从而导致下游补体激活后出现血流紊乱或血管活性和疼痛介质的局部释放。
通过共聚焦荧光显微镜和对比增强超声成像,评估大小分级的微泡在小鼠肾脏微循环中的滞留情况,以评估物理截留、糖萼降解以及补体介导的滞留情况。在微泡给药前后测量尿缓激肽。在脂质微泡给药完成后 7 至 10 分钟,对 13 名人类受试者进行了肾脏对比增强超声检查。
在小鼠和人类中,通过持续的对比增强超声信号增强,在肾脏皮质中检测到微泡滞留。小鼠的微泡滞留与剂量呈线性相关,几乎仅发生在皮质肾小球微血管中。微泡滞留不会影响微球衍生的肾血流。糖萼降解或微泡大小均不会影响微泡滞留,从而排除了滞留的可能性,但在 C3 缺陷型小鼠中,微泡滞留减少了 90%(P <.01)。微泡注射后 5 分钟,尿缓激肽增加了 65%。
脂质壳微泡由于与肾小球微血管内皮的补体介导相互作用而滞留在肾脏皮质中。微泡滞留不会对肾灌注产生不利影响,但会产生补体相关的中间产物,已知这些中间产物介导疼痛感觉,可能是导致侧腹痛的原因。